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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a
chronic lung disease characterized by a progressive air-
flow limitation and associated with an abnormal inflam-
matory response of the lungs to noxious particles or
gases (1,2). COPD ranks among the top five leading
causes of death worldwide and it is estimated that it will
be in the mortality top three by 2020. Annual healthcare
costs are greatly affected by COPD, being estimated at
2.8 × 108 £ in The Netherlands (in 2000), 7.8 × 108 £ in the
United Kingdom (in 1996), and more than 14.5 × 109 US$
direct costs in the United States (in 1993) (2).
Tobacco smoking, the main risk factor, is associated
with about 80% of COPD cases, and this includes passive
smoking (3). Other risk factors include air pollution, the
effects of indoor cooking, and asthma (2–4). However,
only 15–20% of the smokers develop COPD, pointing to
susceptibility factor(s) for COPD. Among these factors
are genotype polymorphisms as exemplified by α1-antit-
rypsin (5) and other gene polymorphisms in molecules
such as tumor necrosis factor (TNF)-α, matrix metallo-
proteinase (MMP), or antioxidant genes (5–9) dependent
on race and COPD phenotype (9).
PATHOGENESIS OF COPD
Airway Remodeling
COPD can be divided based on either clinical mani-
festations or pathological features into three different
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Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease associated with pro-
gressive airflow obstruction. Tobacco smoking is the main risk factor worldwide. In contrast to asthma, anti-
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disorders: chronic bronchitis with airflow limitation,
emphysema, and chronic bronchiolitis. COPD is charac-
terized by a progressive lung function decline, mea-
sured as an increased annual decline in forced
expiratory flow in 1 s (FEV1) (1,2). Research in the past
two decades has shown pathological features of COPD
patients comprising lung tissue remodeling-like
changes in mucosal tissue fiber types and/or fibrosis,
pulmonary and systemic inflammation, lung vascular
remodeling, and declines in skeletal muscle mass and
function (10–17). In emphysema, alveolar septs are dete-
riorated, resulting in reduced gas exchange and loss of
elastic recoil of lung tissue (14). In chronic bronchitis
with airflow limitation, bronchial gland enlargement
and goblet cell hyperplasia leads to overproduction of
mucus, resulting in mucoid airways obstruction (14).
Often, COPD patients show a combination of these dis-
orders. The pulmonary inflammation consists of neu-
trophils, macrophages, CD8+ T-cells (less prominent in
severe COPD), mast cells, and eosinophils during exac-
erbations or in COPD patients showing reversible lung
function (16,18). 
Pathophysiological features in addition to decreased
lung function include chronic cough and dyspnoea. In
smokers, epithelial cell metaplasia often occurs,
whereas in chronic bronchitis, a goblet cell metaplasia is
seen. Both types of metaplasia result in an impaired cil-
iary function. In chronic bronchitis, the hypersecreted
mucus cannot be cleared sufficiently, resulting in
chronic cough and dyspnoea. Although after cessation
of smoking, the decline in lung function is reduced,
lung function will not be restored and an increased air-
way resistance persists (19–20). This is probably due to
pathological alterations in the airways like fibrosis and
inflammation that reduce the diameter of airway lumen.
In addition, after cessation of smoking an airway
inflammation persists, hence contributing to the irre-
versibility of the decreased lung function (10,12,16,18). 
Other disturbed mechanisms are thought to
include oxidative stress and protease–antiprotease
balance (12,16,18). This may be due to genetic predis-
position such as polymorphisms reported for glu-
tathion-S-transferase, epoxide hydrolase, MMPs 1, 9,
or 12, and tissue inhibitor of metalloproteinase
(TIMP) 2 (5–9,21). Alternatively, an imbalance is due
to chronic exposition to cigarette smoke and subse-
quent release of free radicals and proteases such as
elastase and MMPs from activated inflammatory
cells. In turn, this may cause a chronic state of tissue
damage, repair, and remodeling (14). Frequent exac-
erbations in COPD patients may eventually result in
increased airway inflammation with eosinophils and
neutrophils and higher levels of inflammatory medi-
ators such as cytokines (22,23). 
Role of Growth Factors
Growth factors are small to large proteins that are
divided in families based on their structural or func-
tional homologies. The main families include the epi-
dermal growth factor (EGF) family, transforming
growth factor (TGF)-β family, fibroblast growth factors
(FGFs), insulin-like growth factor (IGF) family, platelet-
derived growth factor (PDGF) family, vascular endothe-
lial growth factor (VEGF) family, and hepatocyte
growth factor (HGF). This review will be confined to
EGF-like growth factors, FGFs, VEGF, TGF-β, and spe-
cific cytokines. Growth factors are involved in a variety
of processes including cellular proliferation, differentia-
tion, migration, metabolism, and gene expression.
Recently, localization of EGF-like growth factors in the
human airways such as EGF, TGF-α, heregulins, beta-
cellulin, and heparin-binding EGF (HB-EGF) has been
demonstrated (24). One of the receptors for EGF-like
growth factors, HER1 (EGFR or c-erbB1), has been
shown to be involved in mucus production in goblet
cells either directly via stimulation by TGF-α or HB-
EGF, or indirectly via a variety of molecules including
cytokines such as TNF-α, interleukin (IL)-4 or IL-13, cig-
arette smoke, or neutrophil-derived oxidants (25). In the
airway epithelium of patients with asthma, expression
of HER1, but not of the other HER or EGF family mem-
bers, was enhanced as compared to healthy control sub-
jects (26,27). Increased expression of HER1 has been
advocated for its involvement in epithelial repair and
airway wall remodeling in asthma (27). In the airway
epithelium of patients with COPD, expression of HER1,
heregulin, and EGF was higher as compared to control
subjects (24). In contrast, Vignola et al. (28) could not
find any increased bronchial expression of EGF in
chronic bronchitis patients, perhaps as a result of differ-
ences in the study population. The literature fully sup-
ports the notion that HER1 is involved in hypersecretion
of mucus in chronic bronchitis as well as in neutrophilic
inflammation, and eventually contributes to the pul-
monary tissue remodeling seen in COPD and severe
asthma. Also, EGF-like growth factors may also be
involved in pulmonary tissue remodeling in COPD. 
FGF Family
The FGF family consists of 23 members in man and
their functional receptors are designated FGFR1 to
FGFR5 (29). These FGFs are mitogenic factors involved
in development, tissue homeostasis, and repair
processes; FGF-1 and FGF-2 are also angiogenic factors
(30–32). Among other growth factors, FGF-1, FGF-2, and
FGF-7, as well as their receptors FGFR1 and FGFR2, are
widely distributed in the human lung. In a recent study
from our lab, differences in pulmonary expression of
FGF-1, FGF-2, and FGFR1 were found between non-
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smokers and smokers with or without COPD (15,32).
With regard to FGF-2, airway expression is higher in
bronchial tissue from asthmatics as compared to healthy
control subjects (33). In COPD, expression levels of FGF-
1, FGF-2, and FGFR1 were observed to be increased in
vascular and in epithelial compartments in lungs of
patients with COPD as compared to subjects without
COPD (15,32). FGF-1 can stimulate tissue remodeling
by increasing collagenase expression and downregula-
tion of collagen I expression in lung fibroblasts (30–32).
It is yet unknown whether differences in FGF-7 expres-
sion patterns in lung tissue from patients with and with-
out COPD or asthma exist. These data support a role for
the FGF–FGFR axis in tissue remodeling in COPD.
VEGF Family
The VEGF family consists of seven members (VEGF-
A–F and placenta growth factor [PiGF]), which can bind
to their respective cellular receptors VEGF receptor
(VEGFR)-1 (also referred as Flt-1), VEGFR-2 (or KDR or
Flk-1), and VEGFR-3 (or Flt-4). VEGF is predominantly
known as a paracrine-acting, angiogenic factor stimu-
lating mitogenesis, migration, and permeabilization of
the vascular endothelium. Several studies support the
idea that VEGF and its receptors contribute to tissue
remodeling and disease severity in chronic lung dis-
eases including asthma (34,35). In patients with COPD,
higher pulmonary VEGF expression was found in
bronchial and alveolar epithelial in vascular smooth
muscle as well as alveolar macrophages, whereas
higher VEGFR-1 and VEGFR-2 expression was found in
the endothelium as compared to patients without
COPD (35). In this study, patients were not further strat-
ified into emphysema severity classes. In patients with
severe emphysema, VEGF expression in total lung
extracts has been reported to be lower as compared to
patients without COPD (36). Furthermore, VEGF levels
in induced sputum were higher in patients with chronic
bronchitis and airflow limitation, whereas they were
lower in patients with emphysema as compared to
healthy controls. In agreement with immunohistochem-
ical data from our lab (35), VEGF sputum levels in
patients with chronic bronchitis and airflow limitation
were inversely correlated with FEV1 values (36). These
data point at a COPD stage- and/or subtype-dependent
expression of VEGF. This idea is supported by another
study (37) demonstrating higher VEGF expression in
lung tissue from patients with moderate COPD, but a
lower expression in lung tissue from patients with
severe emphysema as compared to subjects without
COPD. Overexpression of VEGF in mice caused pul-
monary emphysema, aberrant structure of capillary
endothelium, and pulmonary inflammation with
macrophages (38). Also, transgenic overexpression of
PiGF caused apoptosis of pneumocytes, emphysema,
and a reduced endothelial cell number and VEGF
expression (39). In contrast, adult mice in whom pul-
monary VEGF expression was impaired by genetic tar-
getting showed up to 86% lower VEGF levels as well as
VEGFR-2 expression concomitant with alveolar and
bronchial epithelial apoptosis, loss of elastic recoil, and
airspace enlargement but no inflammation (40).
Although inconclusive, these data from animal studies
provided further support for a role of VEGFs and their
receptors in tissue and vascular remodeling seen in
COPD. 
Assigning functional differences of VEGFRs in the
pathogenesis of COPD can further support this.
Activation of VEGFR2 is involved in angiogenesis by
stimulating mitogenesis of endothelial cells during
vascular damage-repair processes (41). In contrast,
VEGFR1 is rather involved in stimulating vascular
smooth muscle MMP activities and endothelial plas-
minogen activator and its inhibitor, activities needed
for blood vessel maturation (41,42). VEGFR-1 is also
involved in inflammation, e.g., by stimulating migra-
tion of monocytes and CD34+ cells (43). Expression of
VEGFR2 during repair is followed by VEGFR1 expres-
sion. As VEGFR1 has a higher affinity for VEGF than
VEGFR2, it is thought that VEGFR1 is involved in the
bronchial angiogenic process (35,37,44). In COPD,
pulmonary vascular expression of VEGF and VEGFR2
were reported to be increased in smokers with COPD
or chronic bronchitis, whereas VEGFR1 expression
did not differ between smokers with or without
COPD (35). In addition, subjects with COPD showed
an increased pulmonary vascular remodeling and
thicker vessel walls (44). In contrast, in subjects with
emphysema, pulmonary VEGF and VEGFR2 expres-
sion is lower as compared to subjects without COPD
(45). Concomitant with the decreased expression,
endothelial cell death and decreased endothelial pro-
liferation occurred (45). Supporting evidence for the
role of VEGFR2 in emphysema was provided in an
animal model in which VEGFR2 was blocked, result-
ing in pulmonary endothelial cell apoptosis and
emphysema (45).
Based on these data, we hypothesize that in COPD/
chronic bronchitis, the higher VEGF and VEGFR2
expression leads to an increased angiogenesis and vas-
cular remodeling, which is inefficiently compensated by
the low expression of VEGFR1. In subjects with COPD/
emphysema, VEGFR2 and VEGF expression are lower.
Because VEGFR1 has a higher affinity for VEGF than
VEGFR2, VEGFR1 scavenges VEGF from VEGFR2,
resulting in specific VEGFR1 activation and in endothe-
lial apoptosis, higher MMP activity, and vascular and
alveolar destruction. Hence, the balance among VEGF,
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VEGFR1, and VEGFR2 is critical in the pathogenesis of
COPD subtypes. 
TGF Family
The TGF-β subfamily has five members, of which
TGF-β1–3 have been shown to be present in mammals.
TGF-β shows a plethora of effects. It is known to act in
a biphasic way on fibroblast proliferation, whereas it
inhibits proliferation of other cells such as epithelial,
endothelial, and smooth muscle cells. In addition, it
stimulates (terminal) differentiation of several cell
types, and enhances synthesis and secretion of extracel-
lular matrix (ECM) proteins such as collagens. TGF-β1
can drive wound repair by cellular migration and cell
flattening toward wound closure, as well as restoration
of tissue differentiation. A recent study pointed out
that overexpression of TGF-β1 in mice leads to Smad3-
dependent pulmonary expression of procollagens and
antiproteinases as well as fibrosis (46). On the other
hand, TGF-β is chemotactic for monocytes/ macrophages
and mast cells. Several studies provided evidence for an
aberrant pulmonary expression of TGF-β1 in patients
with COPD. Pulmonary TGF-β1 protein and mRNA
expression was higher in lung tissue including airway
epithelial cells of patients with mild to moderate COPD
(47–49). The higher expression correlated with the
increased number of macrophages in the airways (47),
supporting a role for TGF-β1 in the pathogenesis of
COPD. Baraldo et al. (50) demonstrated that bronchial
glands of patients with chronic bronchitis with airway
obstruction have fewer cells showing a positive TGF-
βRII staining as compared with smokers without
COPD. No differences between the patients groups
were found with regard to the number TGF-β1-positive
cells. Thus, the literature supports the idea that the role
of TGF-β1 in COPD is dependent on the COPD subtype.
AIRWAY SMOOTH MUSCLE AND ECM 
Focus is now on the bi-directional relationship
between airway smooth muscle (ASM) cells and the
ECM. Evidence is mounting that ASM cells can modu-
late ECM homeostasis as they express and release a
variety of ECM proteins (51). Altered ECM deposition
contributing to the airway wall remodeling is an
important feature of chronic airway diseases such as
asthma and COPD. We have demonstrated the
increased bronchial deposition of ECM proteins, such
as collagen I and III, fibronectin, and laminin as part of
the airway remodeling process in patients with COPD
(52). Staining for fibronectin was increased in bronchial
blood vessels and for laminin in ASM as well as the
microvasculature in patients with COPD as compared
to controls (52). The synthetic capabilities of ASM cells
in response to various mediators such as serum, TGF-β,
and LTD4 are documented by the fact that they can pro-
duce fibronectin, perlecan, elastin, laminin (α1, β1,β2,γ2),
and various collagen subtypes (51–55). Under chronic
inflammatory conditions, a number of cytokines and
leukotrienes are produced in airways, which could
directly act on ASM cells. In addition to their role in
ECM deposition, ASM cells have been shown to have
the capacity to produce MMPs (54,55), which include
the collagenases, gelatinases, stromelysins, elastases,
and membrane-bound forms. MMPs are secreted in
inactive form and are tightly regulated by TIMPs (56),
thus eventually contributing to the alteration in ECM.
ECM remains in a state of dynamic equilibrium of new
synthesis and degradation controlled by the actions of
MMPs and their tissue inhibitors (TIMPs). ASM con-
tributes to this equilibrium by producing both ECM
proteins (51) and MMPs and TIMPs (56), as well as
growth factors such as TGF-β1 (57) and connective tis-
sue growth factor (CTGF) (58). 
In turn, ECM proteins promote the survival, prolifer-
ation, cytokine synthesis, migration, and contraction of
human ASM cells. There is accumulating evidence that
ECM, in turn, alters a number of aspects of ASM biology
through integrin signaling (52,55). Thus, the inter-
twined relationship of ASM and ECM and their
response to stimuli such as chronic inflammation in dis-
eases like asthma and COPD contribute to the remodel-
ing seen in airways of patients with these diseases. 
CYTOKINES AND CHEMOKINES 
Inflammatory cells of both the innate and the
acquired immune system seem to play an important
role in the pathophysiology of COPD (14,16,18). In
patients with COPD, higher numbers of macrophages
and CD8+ T-cells were found in the airway walls and in
vascular smooth muscle, whereas more neutrophils
were observed in bronchial glands and the airway
lumen (16,18). Both cytokines and chemokines provide
a chemotactic gradient and can activate these cells.
Classical cytokines include ILs, interferons, and TNF-α.
Based on structural homology around four cysteine
residues, chemokines can be subdivided into four sub-
classes, -C- , -CC- , -CXC- , and -CXXXC-, in which X
substitutes for any amino acid. Two subclasses account
for most of the chemokines: CXC (α) and CC (β)
chemokines (59). Cytokines and chemokines are syn-
thesized by both structural cells (such as fibroblasts
and epithelial, endothelial, and muscle cells) and
inflammatory cells of the innate and the adaptive
immune system. They act via specific membrane-
bound receptors resulting in cell-specific reactions.
With regard to COPD, protein and/or mRNA levels of
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different cytokines and chemokines have been found to
be altered compared with subjects without COPD
(Table 1). Among these, TNF-α or TNF-α receptor
(TNFR) levels, soluble IL-1 receptor antagonist (sIL-
1Ra), CCL2 (or monocyte chemoattractant protein
[MCP]-1) and its receptor CCR2, CCL3 (or macrophage
inflammatory protein [MIP]-1α), and CCL4 (or MIP-1β)
and their receptor CCR5, CXCL8, (or IL-8), and
CXCL10 (or interferon-inducible protein [IP]-10) can be
discerned as pro-inflammatory factors. In Fig. 1, a brief
outline of the proposed remodeling and inflammatory
mechanism in COPD is provided (18,59). Based on this,
specific anti-inflammatory therapies are being devel-
oped for COPD (60). In addition to the inflammatory
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Table 1
Expression and Polymorphisms of Growth Factors, Cytokines, 
and Chemokines in Chronic Obstructive Pulmonary Disease (COPD)
Molecule Producta Compartmentb Datac
EGF Protein Lung tissue ↑ (CB)
EGFR Protein Lung tissue ↑ (COPD)d
HER3 Protein Lung tissue ↑ (COPD)
FGF-1 Protein Lung tissue ↑ (COPD)
FGF-2 Protein Lung tissue ↑ (COPD)
FGFR1 Protein Lung tissue ↑ (COPD)
TGF-β1 Protein Lung tissue ↑ (COPD)
mRNA Lung tissue ↑ (COPD)
VEGF Protein Lung tissue ↓ (emphys)
Lung tissue ↑ (COPD)
Protein sp ↓ (emphys) 
sp ↑ (COPD)
VEGFR1 Protein Lung tissue ↑ (COPD)
VEGFR2 Protein Lung tissue ↓ (emphys)
↑ (COPD)
TNF-α Protein ser, sp, leg muscle ↑ (COPD)
mRNA ser, sp ↑ (COPD)
Polymorph Gene yes (COPD)
sTNFR p55 Protein spe ↑ (COPD)
sTNFR p75 Protein ser ↑ (COPD)
CCL2 mRNA Lung tissue ↑ (COPD)
Protein sp, BAL ↑ (COPD)
CCR2 mRNA Lung tissue ↑ (COPD)
Protein Lung tissue ↑ (COPD)
CXCL1 Protein sp, Lung tissue ↑ (COPD) 
CXCL8 mRNA Lung tissue Higher
Protein ser, sp, BAL
Lung tissue Higher
CXCR2 Protein PBL Higher
mRNA BAL cells Higher
aPolymorph, polymorphism; no., number; epi, bronchial epithelial. 
bser, serum; sp, induced sputum; BAL, bronchoalveolar lavage; PBL, peripheral blood lymphocytes.
cExpression or levels in COPD as compared to controls; yes, polymorphisms reported; CB, chronic
bronchitis; emphys, severe emphysema.
dEx-smokers with COPD.
eInverse correlation with FEV1. Data were obtained from references (15,16,24,28,35–37,47,48,59,
60,72).
effects, recent studies provided more evidence that
cytokines and chemokines are also involved in tissue
remodeling.
Several studies have shown that epithelial cells
express the CXCL8 receptor CXCR2 suggesting a role
for CXCL8/CXCR2 in wound repair (18). In vivo,
impaired CXCR2 expression in mice resulted in delayed
skin wound repair as compared to wild-type mice,
which could not be restored by exogenous CXCL8
application (61). Alternatively, topical application of
CXCL1 or CXCL8 stimulated human skin wound repair
in chimeric mice (62). The role of CXCL8 in wound
repair was further substantiated by in vitro experi-
ments. These data support a direct role for CXCL8 in
repair of epithelial injury often seen in airway epithe-
lium in COPD (18).
CCL2 and CCL3 are produced by a variety of cells
including macrophages and endothelial and epithelial
cells. Wound healing studies in mice and man demon-
strated that CCL2 and CCL3 expression are enhanced
during repair of injured skin (63) or skeletal muscle in a
time-dependent manner and coinciding with macro-
phage influx. TNF-α seems to be involved in the regula-
tion of CCL2 expression, as TNF-α scavenging with a
TNF-α antibody reduced CCL2 levels during wound
repair (63). 
In vitro, CCL2 and its receptor, CCR2, were demon-
strated to be directly involved in endothelial and lung
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Fig. 1. Simplified scheme of cytokine and growth factor actions in human airways. On triggering, e.g., with tobacco
smoke, epithelial cells are damaged, epithelial cells and resident macrophages produce inflammatory mediators such as
tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-8. In turn, inflammatory mediators-stimulate migration of mono-
cytes/macrophages, neutrophils, and CD8+ T-lymphocytes to the airway. Both TNF-α and IL-8 can cause degranulation of
neutrophils with production and release of serine-proteinases and matrix metalloproteinases (MMPs) as well as free radi-
cals that can cause matrix and epithelial damage. In turn, TNF-α and released growth factors such as vascular endothelial
growth factor (VEGF) and fibroblast growth factor (FGF)-1 and -2 orchestrate epithelial repair. Ongoing inflammation and
tissue breakdown trigger the release of growth factors such as transforming growth factor (TGF)-β1, inducing extracellular
matrix (ECM) production by myofibroblasts. Repetitive tissue damage and repair can lead to excessive ECM deposition and
subepithelial fibrosis. Neu, neutrophil; Mϕ, macrophage; T, CD8+ T-lymphocytes. 
epithelial cell proliferation and migration and wound
closure (18,64,65). In addition, CCL2 was found to stim-
ulate collagen synthesis in rat lung fibroblasts via a
TGF-β1-dependent pathway, hence potentially con-
tributing to a fibrogenetic remodeling as seen in COPD
(66). In turn, TGF-β1 was reported to induce CCL2 pro-
tein levels via downstream intracellular mechanisms
including reactive oxygen species, mitogen-activated
protein kinase (MAPK) p38, and p42/44 in mesangial
cells (67). Hence the CCL2–TGF-β axis may potentially
contribute to fibrogenetic remodeling as seen in COPD.
CURRENT THERAPY FOR COPD
Current therapies for COPD are predominantly based
on anti-inflammatory drugs for treating asthma. These
include corticosteroids or theophylline with or without
bronchodilators, including β2-agonists (1,68). Upon
treatment with corticosteroids, some studies reported
reduction of the number of exacerbations and improved
quality of life assessed with FEV1 values after short- or
long-term treatment (69), or no effect on lung function.
However, steroid treatment in COPD is rather ineffective
in reducing airway inflammation and the decline in lung
function, in contrast to steroid treatment in patients with
asthma and COPD with bronchial hyperresponsiveness
and eosinophilia. Furthermore, side effects of steroids
include increased risk of hip fractures, skin bruising, and
candidiasis, and the airway remodeling is not positively
affected by the current treatment. 
Novel possible broad-acting inhibitors of inflamma-
tion include specific inhibitors of phosphodiesterase 4
(PDE4), leukotriene receptor antagonists, inhibitors of
5-lipoxygenase (leukotriene synthesis inhibitor), and
cyclo-oxygenase (COX) inhibitors (which inhibit
prostaglandin synthesis) (70,71). However, more spe-
cific therapies directed against inflammation and
remodeling without adverse effects are needed. Anti-
inflammatory cytokine antagonists seem useful in sev-
eral Th1- cytokine-driven diseases, such as rheumatoid
arthritis (RA), psoriasis, and inflammatory bowel dis-
ease or Crohn’s disease. Inhibitors of remodeling
include antagonists for growth factors such as TGF-β
and VEGF, and inhibitors of MMPs. This part of the
review focuses on the recent developments in this field.
POTENTIAL DRUGS: GROWTH FACTOR 
OR CYTOKINE ANTAGONIST DRUGS
Different intervention levels can be explored.
Currently examined levels of intervention include (1)
scavenging and neutralization of proteins by binding to
soluble receptors or neutralizing antibodies; (2) inhibi-
tion of protein binding to its receptor by small com-
pounds or incomplete and nonactivating cytokines; (3)
inhibition of protein activation (processing of preprotein
into mature protein); and (4) inhibition of signal trans-
duction and transcription via inhibition of receptor-
dependent tyrosine kinases, MAPKs, or nuclear factor
(NF)-κB and its inhibitors IKK and IκB and via antisense
mRNA or small interfering (si)RNA molecules for
growth factors or cytokines. Many potential drugs are
still in preclinical development or in clinical trial phases
for diseases other than COPD (Tables 2 and 3). A few are,
however, in clinical trials, with little information on them
having been published for COPD in peer-reviewed jour-
nals. General adverse effects of injected drugs include
reactions around the site of administration and, less fre-
quently, a delayed hypersensitivity-like reaction and new
onset of autoimmunity; on rare occasions, drug-induced
systemic lupus erythematosis and demyelination, serious
infections, vasculitis, or malignancies can occur (59,60).
This may lead to a loss of efficacy. In the following sec-
tions, some potential drugs are highlighted.
EGFR/HER
Little has been published on the expression of EGF-
like growth factors and HER1-family members in
COPD. A few studies reported a higher expression of
HER1, EGF or heregulin in airway epithelium in
patients with chronic bronchitis or COPD (24,28,72). A
recent study also demonstrated a higher bronchial
epithelial expression of HER3 in patients with COPD as
compared with smokers without COPD and healthy
subjects (72). Several studies pointed to the involvement
of HER1 in mucus overproduction and goblet cell meta-
plasia. This supports a potential targeting of these mol-
ecules for treatment of tissue remodeling in COPD.
Among the antagonists of HER1 or HER2–4 as well as
inhibitors of their ligands are antibodies directed
against the ligand-binding site such as cetuximab and h-
R3, or small molecules directed against the tyrosine
kinase domain such as gefitinib or trastuzumab. Several
of these antagonists are already in clinical phase studies
or are already approved by the Food and Drug
Administration (FDA) for treatment of specific cancers
(cetuximab, erlotinib, trastuzumab, gefitinib) (Table 2). 
Cetuximab is a chimeric immunoglobulin (Ig)G1 anti-
body binding to the extracellular domain of HER1, block-
ing ligand binding. Although approved by the FDA for
use in metastatic colon cancer, it is in clinical trial for dif-
ferent carcinomas. One of the adverse effects is the devel-
opment of interstitial lung disease, which is not favorable
for patients with COPD. Another antagonist against the
extracellular domain of HER1 is h-R3, a humanized anti-
body IgG1. It inhibits proliferation of carcinoma cells both
in vitro and in vivo and VEGF expression, angiogenesis,
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Table 2
Examples of Antagonists in Clinical Trial: Potentially Useful Drugs 
for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Name Type of compound Function Trial phase (disease)
EGFR/HER2
Cetuximab Chimeric IgG1 human/mouse blocking ligand 1(CC)
(IMC-225; Erbitux) Antibody binding to extracellular binding
domain of EGFR
h-R3 Humanized IgG1 antibody binding blocking, ligand binding IIb (HNC)
to extracellular domain of EGFR
ABX-EGF Human IgG2 monoclonal  antibody blocking ligand II (RCC)
against human EGFR binding
Erlotinib Oral 4-anilinoquinazoline inhibiting EGFR 1(NSCLC)
(Tarceva; OSI-774) tyrosine kinase 
Gefitinib Oral 4-anilinoquinazoline inhibiting EGFR 1(NSCLC)
(Iressa; ZD1839) tyrosine kinase
Lapatinib Small molecule inhibitor inhibiting EGFR & HER2 III (BC; cancer)
(GW572016) tyrosine kinase
PKI166 Oral pyrrolo-pyrimidine derivate inhibiting EGFR& HER2 II (ST)
tyrosine kinase
Canertinib 4-Anilinoquinazoline derivate inhibiting pan-HER I (BC)
(CI1033;PD 183805) tyrosine kinase
TNF-α
Infliximab Chimeric IgG1 human/mouse Neutralization 1(RA;CD) (Remicade)
anti-TNF-α antibody TNF-α III (AS; psoriasis); 
II (COPD; asthma)
Etanercept Human TNFR p75 :Fc IgG1 Neutralization 1(RA;AS);
(Enbrel) fusion protein TNF-α II (asthma)
Adalimumab Human IgG1 anti-TNF-α Neutralization 1(RA); 
(Humira) antibody TNF-α III (AS;CD);
II (psoriasis)
Afelimomab Mouse F(ab’)2 anti- Neutralization III (sepsis) 
(Segard) TNF-α fragment TNF-α
CDP-571 Humanised mouse Neutralization III (CD)
(Humicade) anti-TNF-α antibody TNF-α
CDP-870 Polyethylene-glycolated-human Neutralization III (RA;CD)
F(ab’) anti-TNF-α fragment TNF-α
Onercept Rec. human sTNFR p55 Neutralization II (CD; psoriasis)
TNF-α
PEG sTNF—RI Polyethylene-glycolated-human Neutralization II (RA)
rec. soluble TNF- receptor p55 TNF-α
CytoTab Sheep F(ab’) anti-TNF-α Neutralization IIb (sepsis);
antibody TNF-α I (CD)
ISIS-104838 Antisense TNF-α Inhibition TNF-α II (RA;CD) 
methoxy-oligonucleotide transcription
BMS-561392 TACE & MMP Blocks pre-TNF-α II (RA;CD) 
Inhibitor processing
Marimastat TACE & MMP Blocks pre-TNF-α III (cancer) 
Inhibitor processing
CCL2/CCR2
MLN-1202 humanized mouse Inhibits binding II (RA)
anti CCR2 antibody CCL2 to CCR2
(continues)
and tumorigenesis in mice and man (73). In contrast to
the small-molecule HER1 inhibitor ZD1839, h-R3 does not
stimulate epithelial apoptosis (73). Potentially, this drug
may reduce goblet cell hyperplasia as seen in smokers
with COPD, or vascular remodeling or angiogenesis as
can be observed in patients with emphysema. Trastu-
zumab (Herceptin) is a recombinant humanized murine
anti-HER2 monoclonal antibody. It is approved by the
FDA for treatment of metastatic breast carcinoma. It
induces HER2 receptor downmodulation, inhibits critical
signaling pathways (i.e., Ras-Raf-MAPK and PI3K/Akt),
blocks cell cycle progression by inducing the formation of
p27/Cdk2 complexes, and inhibits HER2 cleavage and
angiogenesis (74). 2C4 is a humanized monoclonal anti-
body targeting the role of HER2 as a co-receptor by steri-
cally hindering HER2 recruitment in heterodimers with
other HER receptors (74).
Among the small molecules against HER1 is gefitinib
(Iressa; ZD1839). This is a 4-anilinoquinazoline target-
ting the ATP-binding site in the intracellular tyrosine
phosphorylation site of growth factor receptors includ-
ing HER1 and HER2 (75). It has been approved by the
FDA for use in local or metastatic non-small-cell lung
carcinoma (NSCLC). Although capable of reducing
tumor growth, it stimulates caspase-dependent apopto-
sis of lung epithelial cells in vitro (76). This is an effect
that is not favorable in case of emphysema, in which
alveolar epithelial cells are being lost presumably via
apoptosis. PKI166 is an oral pyrrolo-pyrimidine derivate
inhibiting HER1 and HER2 tyrosine kinase activity.
PKI166 is capable of reducing tumor growth but also
stimulates epithelial intercellular adhesion and inhibits
angiogenesis associated with an impaired VEGF and
CXCL8 expression as well as endothelial apoptosis in
human carcinoma growing in mice (77). Especially the
re-establishment of epithelial adhesion, reduction of
CXCL8 expression, and inhibition of angiogenesis may
be favorable in treatment of patients with COPD, poten-
tially leading to intact airway epithelium, reduced neu-
trophilic inflammation, and less vascular remodeling.
The water-soluble, orally available 4-anilinoquinazo-
line canertinib (CI-1033) is a specific pan-HER1-4 tyro-
sine kinase inhibitor, thereby potentially impairing HER
functioning. All of these compounds may reduce exces-
sive proliferation and mucin synthesis as seen in
chronic bronchitis. On the other hand, further epithelial
and endothelial apoptosis, as seen with trastuzumab,
should be avoided in patients with emphysema.
However, no data have yet been published on its effi-
cacy for reducing tissue remodeling in the treatment of
nononcological disorders.
VEGF AND VEGFR, FGF AND FGFR.
Several studies have pointed to the involvement of
VEGF/VEGFR in pulmonary and vascular remodeling
and inflammation. VEGF transgenic mice showed
alveolar vascular and airspace remodeling as well as
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Table 2 (continued)
Name Type of compound Function Trial phase (disease)
INCB3284 CCR2 antagonist Inhibits binding I (DTH, RA)
CCL2 to CCR2
RS-504393 spiropiperidine Inhibits binding Preclinical
CCL2 to CCR2
MCP-1(9–76) CCL2 peptide equal to Inhibits binding Preclinical
amino acids 9 to 76 CCL2 to CCR2
CXCR2
SB332235 CXCR2 antagonist Inhibits binding I (COPD)
CXCL8 to CXCR2
SB656933 CXCR2 antagonist Inhibits binding I (COPD)
CXCL1 to CXCR2
SB265610 biphenolic urea derivate Inhibits CXCL1/8 Preclinical
to CXCR2
SB225002 biphenolic urea derivate Inhibits CXCL1/8 Preclinical
to CXCR2
GROa[8ñ73) CXCL1 peptide equal to Inhibits CXCL1 Preclinical
amino acids 8 to 73 binding to CXCR2
AS, ankylosing spondylitis; BC, breast tumours; CC, colon cancer; CD, Crohn’s disease; HNC, head and neck cancer; DTH,
delayed type hypersensitivity; HIV, human immunodeficiency virus; MS, multiple sclerosis; NSCLC, non-small-cell lung cancer;
RA, rheumatoid arthritis; RCC, renal cell cancer; ST, solid tumors; 1, approved by the US Food and Drug Administration (FDA). 
increased numbers of alveolar macrophages, or a Th2-
type airway inflammation in a murine asthma model
(78). An in vitro study demonstrated that VEGF
induced monocyte migration via VEGFR1 expressed
by monocytes (78,79). Therefore, such inhibitors may
be of potential use for treatment of vascularization, as
seen in asthma or in specific subtypes of COPD, such
as chronic bronchitis, but not emphysema. Several
drugs have been developed to reduce tumor growth
and metastasis by impairing the neovascularization.
Antagonists include those in clinical trials and in pre-
clinical investigations. Among those in clinical trial are
VEGF-Trap, bevacizumab (or: Avastin), CEP-7055,
VEGF Trap, and PTK787 (79).
Avastin is a humanized monoclonal IgG1 antibody
against VEGF preventing binding of VEGF to VEGFR1
and VEGFR2. The FDA has approved it for intravenous
treatment of metastatic colon and rectal cancer. Clinical
studies have pointed out that this antibody has little clin-
ical activity as a single drug, but in combination with
chemotherapy in the treatment of a variety of cancers, it
reduced tumor growth and angiogenesis (80). Side effects
of Avastin were noted to include thrombosis and hyper-
tension and, in combination with chemotherapy, cere-
brovascular and cardiovascular infarctions (80).
CEP-7055 is a small-molecule, water-soluble indenopy-
rrolocarbazole derivate inhibitor of pan-VEGFR tyrosine
kinase activity. CEP-7055 is reported to inhibit pul-
monary VEGFR2 activation in mice, capillary formation
by human and rat endothelial cells in vitro and in vivo in
mice, granuloma formation and vascularization in a
chronic inflammation model in mice, and tumorigenesis
(80,81). It is currently being evaluated in phase-I trials for
treating patients with solid tumors. VEGF Trap is a solu-
ble VEGFR constructed from VEGFR1- and VEGFR2-
binding domains linked to an IgG1 constant region.
Different in vivo mouse models demonstrated that VEGF
Trap reduced hemangiogenesis, lymphangiogenesis, and
tumor growth and size (81). VEGF Trap entered clinical
trial phase-I studies for treatment of solid tumors.
However, little is known yet of side effects or its efficacy
in treatment of chronic inflammatory diseases. 
SU6668 is a IgG2a fusion protein inhibiting tyrosine
kinase activity of FGFR1, VEGFR2, and platelet growth
factor receptor b. SU6668 was demonstrated to inhibit
tumor growth, lung cancer metastasis, and tumor vascu-
larization (82). Its broader spectrum of inhibitory effects
may be more effective in treating airway remodeling in
COPD. Many other small-molecule VEGFR inhibitors are
being developed for clinical therapy (38,82). Despite
these data, nothing has been published yet on such treat-
ments in asthma or COPD. Also, the redundancy of the
VEGF–VEGFR system may temper applicability and effi-
cacy of VEGF/VEGFR inhibitors (83). In addition, in, e.g.,
patients with emphysema, inhibitors of apoptosis are
needed whereas in contrast to chronic bronchitis, expres-
sion of hypoxia-inducible factor, VEGF, and VEGFR2
may be stimulated to overcome endothelial and epithe-
lial cell death and improve vascular restoration (84).
Hence, treatment with VEGF/VEGFR inhibitors should
be further investigated and may be restricted to specific
subtypes of chronic lung diseases.
TGF-Β AND TGF-ΒR
Both pulmonary TGF-β1 and FGFR1 expression have
been reported to be enhanced in COPD as compared to
smokers without COPD. The expression patterns were
reported to be related to either inflammation or tissue
remodeling (15,32,47). One of the involved mechanisms
may include TGF-β1, which can induce FGFR1 and
FGFR2, but not HER1, expression in human lung fibrob-
lasts in vitro (85). The enhanced expression of TGF-β1-
or TGF-β-mediated pathways may hence be a target for
therapeutic intervention. 
A few inhibitors have been reported to reduce TGFβ1
expression, scavenge TGFβ, interfere with binding of
TGFβ to its receptors, or to inhibit TGFβR signal trans-
duction. All of these antagonists are still in preclinical
development. The adenoviral 5 vector encoding for
TGF-β1 antisense RNA molecules was reported to
reduce TGF-β1 expression, leading to impaired collagen
and smooth muscle cell actin in liver cells in mice (86).
The recombinant TGF-β1 peptide coding for amino acids
41 to 65 antagonizes TGF-β1 binding to its receptor. The
peptide stimulated re-epithelialization of skin wounds
in mice with concomitant reduction of wound contrac-
tion and scarring (87). As lung epithelial damage is often
seen in smokers with or without COPD, and epithelial
TGF-β1 expression is higher in airway epithelium in
COPD, molecules such as TGF-β1 (AA41–65) may be useful
in epithelial repair. Soluble TGF-β receptor molecules
TGF-βRII and TGF-βRIII were shown to reduce mam-
mary tumor metastases or airway fibrosis while TGF-β
function in normal tissues remained intact (87,88).
However, Lutgens et al. (89) found that sTGF-βRII
reduced fibrosis in an artherosclerosis mouse model
while increasing T-cell inflammation. As patients with
COPD also show higher numbers of T-cells, modulating
TGF-βRII functioning may have adverse effects in
patients with COPD. 
CYTOKINES 
As pointed out previously, cytokines and chemokines
are not only involved in innate and acquired immunity
processes but also may be involved in tissue remodeling
in chronic lung diseases like COPD. We recently reviewed
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potential antagonists regarding cytokine therapy for
COPD patients summarized a plethora of molecules (60).
Important potential targets for therapy include TNF-α,
CCL2, CXCL1, and CXCL8 and their respective receptors.
This section outlines drugs that may be potential for ther-
apy of patients with COPD.
The pro-inflammatory cytokine TNF-α activates and
stimulates migration of monocytes, macrophages, neu-
trophils, and T-cells. Higher levels of TNF- α have been
observed in induced sputum and plasma in patients with
COPD (Table 1). Studies on gene-activating polymor-
phisms suggested that TNF-α polymorphisms rely on dif-
ferent populations (e.g., Japanese vs Caucasian) and the
location (e.g., –376G/A, –308, –238G/A, +489G/A) (6,90).
However, polymorphisms seem to be associated with a
poorer prognosis (90). TNF-α was shown to play a role in
cigarette smoke-induced emphysema and airway inflam-
mation with neutrophils and macrophages in mice (91). In
addition, following exposure to cigarette smoke, TNFR
p55- and p75-deficient mice had threefold less increase in
airspace enlargement, 65% fewer neutrophils, and no
increase in macrophage numbers in the bronchoalveolar
lavage (BAL) fluid as compared with wild-type mice (92). 
Drugs aimed at reducing TNF-α levels have been
developed for treating chronic diseases such as rheuma-
toid arthritis, psoriasis, and inflammatory bowel dis-
ease (especially Crohn’s disease) (Table 2). Some are in
clinical trial (phase II) for asthma or COPD (Table 2).
TNF-α and TNFR antagonists include antibodies (inflix-
imab, afelimomab, CytoTab, adalimumab, CDP-571,
CDP-870), soluble TNFR (Onercept, Etanercept), small
molecules (ISIS-104838), and inhibitors of TNF-α-con-
verting enzyme (TACE). 
Recent studies have shown that treating patients
with COPD with infliximab over 6 to 24 wk did not
improve lung function, body weight, quality of life
scores, airway inflammation, or cytokine levels (93–95).
One study reported higher exhaled nitric oxide (NO)
levels (93), whereas another study noted a tendency to
improved 6-min walking distance (94). Subgroup analy-
sis of COPD patients in different GOLD stages may
reveal more details. In asthma, short-term treatment
with etanercept enhanced TNFR p75 levels in the
bronchial epithelial lining fluid but did not change air-
way eosinophilia or hyperresponsiveness (96). In a 10-
wk treatment study, Berry et al. (97) reported that
etanercept improved the hyperresponsiveness by
methacholine testing (PC20) and FEV1 (postbronchodila-
tor) as well as the quality of life scores as compared to
treatment by placebo. However, no changes in inflam-
matory or total cell counts in sputum were noted.
TNF-α antagonists not only reduce inflammation
but also tissue destruction by downregulation of MMP
expression or inhibition of MMP activation (98,99).
Mucin 5AC (MUC5AC) is an important constituent of
mucus seen in chronic bronchitis. A potential therapeu-
tic effect of infliximab was described by inhibiting the
TNF-α-induced expression of MUC5AC by an airway
epithelial cell line (100). Other experimental TNF-α
antagonists include the inhibitors of TACE such as
Marimastat and BMS-561392 (Table 2). These molecules
inhibit both pre-TNF-α cleavage into mature TNF-α
and are inhibitors of MMPs. Recent studies demon-
strated that cigarette smoke and lipopolysaccharide
(LPS)-induced MUC5AC production in vitro via a
TACE-dependent mechanism (101). Inhibition of TACE
via TACE-specific drugs would appear to be potentially
beneficial, especially in COPD/chronic bronchitis or
asthma. However, side effects may include muscu-
loskeletal pain, inflammatory polyarthritis, and hand
contraction, potentially precluding its applicability
(102). The concomitant inhibition of MMP activity may
be important in restoration of the protease–antipro-
tease balance in COPD, which favors proteolytic break-
down of tissue at higher MMP and elastase activities.
Among the preclinical drugs is TMI-1, a thiomorpho-
linecarboxamide derivative, which specifically inhibits
LPS-induced TNF-α secretion, but not secretion of
other proinflammatory cytokines such as IL-1β, IL-6, or
IL-8, both from human cell lines and in human explants
(103). In vivo, TMI-1 reduced clinical symptoms in a
collagen-induced arthritis model in mice (103).
Given the side effects, smaller noninjectable, bio-
active molecules with long half-life and high bioavail-
ability that are capable of regulating TNF-α expression,
synthesis, and/or secretion seem to be needed (104).
The antisense oligonucleotide for TNF-α (ISIS-104838)
is an example of an orally available molecule in clinical
trial for RA and Crohn’s disease (Table 2). ISIS-104838
inhibits TNF-α mRNA translation into pre-TNF-α pro-
teins, finally resulting in reduced extracellular TNF-α
levels. Furthermore, TACE-specific siRNA, which
blocks TACE mRNA synthesis, may prove to be useful,
but little is known yet about the clinical effects.
Inhalation antisense formulations are less likely to
reduce systemic pulmonary inflammation in COPD,
but may be useful in treating local pulmonary inflam-
mation, and hence reduce tissue remodeling and
mucus hyperproduction. In conclusion, given the selec-
tive efficacy of TNF-α antagonists, clinical trials for
COPD with different antagonists other than infliximab
seem worthwhile for determining efficacy.
CHEMOKINES
Macrophages migrate toward a gradient of CCL2,
CCL3, or CCL4 via their receptors CCR2 or CCR5.
Neutrophils are mainly attracted by CXCL1 and CXCL8
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via CXCR1 and CXCR2, of which CXCR1 has a larger
affinity for CXCL8 than for CXCL1. CXCR1 is involved
in neutrophilic degranulation, protease release, and
oxidative stress. T-cells may have receptors for CCL2–4,
and a subset also has CXCL10 receptors (CXCR3). In
COPD, levels of some of these chemokines and their
receptors may be associated with lung function (Table 1),
and seem to be involved in the pathogenesis of COPD
(60). As previously pointed out, chemokines seem to be
involved in tissue repair processes (18,61). Therefore,
chemokine antagonists might have potential as specific
treatments for both inflammation and tissue remodeling
in COPD. A few of the many chemokine and chemokine
receptor antagonists are in clinical trials for inflamma-
tory diseases (Table 2) (60). These include an anti-CCR2
antibody (MLN1202) and small-molecule inhibitors
INCB3284, SB332235, and SB656933 (60). For most drugs,
no peer-reviewed data on effects on tissue remodeling
have yet been published. However, RS-504393—a pre-
clinical CCR2 spiropiperidine antagonist—was shown
to be capable of blocking CCR2-dependent renal fibrosis
apart from reducing macrophage infiltration and activa-
tion and CCL2 expression in mice (105). Among the
CXCL1 and CXCL8 antagonists that prevent binding to
CXCR2, SB332235 and SB656933 are being evaluated in
clinical trial phase I for COPD (Table 2). Whereas both
drugs impair CXCR2-mediated effects on neutrophils,
no data on human lung tissue remodeling or inflamma-
tion have yet been published for both drugs. 
In contrast, SB225002 and SB265610 inhibit binding
of CXCL1 and CXCL8 to CXCR2 by interfering with the
chemokine binding sites (60). SB265610 treatment inhib-
ited skin wound repair and neutrophil recruitment in a
skin wound healing model in mice (61). Although
inflammation can be reduced, a potential drawback of
cytokine antagonists may be caused by the lung epithe-
lial expression of functional chemokine receptors CCR2
and CXCR2, which are probably involved in epithelial
migration and wound healing (18,65). Inhibition of
these receptors may impair wound healing following
smoke exposure and hence, may increase the risk of
infection and concomitant inflammation. In conclusion,
chemokine antagonists may reduce pulmonary inflam-
mation, but they may hamper epithelial repair upon




An alternative and recently explored route either to
reduce growth factor, cytokine, or chemokine levels or
to impair their effects is to interfere with gene expres-
sion or intracellular signal transduction. For growth
factors, receptor tyrosine kinases are needed in order
to activate downstream acting Ras, Raf, and MAPK
p42 and p44 proteins. For cytokines and chemokines,
signal transduction molecules such as NF-κB and
MAPK p38 are needed. NF-κB is both a signal trans-
duction and a transcription factor. In its inactive state,
it is bound to another protein, Inhibitor of κB (IκB).
Upon phosphorylation of IκB by IκB Kinase (IKK), IκB
dissociates from the complex and becomes ubiquiti-
nated and subsequently degraded. Then, activated
NF-κB is translocated to the nucleus and binds to NF-
κB binding sites in the promoter region of genes
including cytokines, chemokines, and MMPs. MAPK
p38 is activated via upstream signaling proteins
including G protein-coupled receptors. MAPK p38 is
involved in the regulation of transcription factors and
a variety of enzymes including those involved in his-
tone remodeling (106). Studies have suggested that
NF-κB and MAPK p38 are involved in the pathogene-
sis of COPD (106,107). The therapeutic effects of antag-
onists may be achieved at the transcription level of
these signaling molecules by blockade of intracellular
translocation of NF-κB, reduction of signaling of NF-
κB by inhibition of IκB degradation, and inhibition of
enzyme activity (108). Several antagonists of MAPK
p38 (SB681323, RWJ67657, SCIO-469), NF-κB (siRNA),
or IKK (BMS345541) are in preclinical or clinical trial
phase I or II for inflammatory diseases including aller-
gic rhinitis and COPD (60,109). As MAPK p38 has four
isozymes and each MAPK p38 inhibitor has its own
specificity toward one or more of these isozymes, this
specificity may cause differential effects. With respect
to NF-κB, several studies have indicated the involve-
ment of NF-κB in tissue remodeling. Using an in vivo
model for intestinal disease, Lawrance et al. (110)
reported that treatment of mice with antisense NF-κB
p65 reduced the intestinal fibrosis. 
In rat tracheal explants, the NF-κB inhibitor SN50
inhibited both TGF-β1 and procollagen I expression that
was enhanced by exposure to diesel exhaust particles
(111). Using siRNA directed against the NF-κB subunit
p65 in airway epithelial cell lines caused an impaired
TNF-α-induced NF-κB p65, IL-6, and CXCL8 expression
(112). Hence, NF-κB inhibitors may potently reduce not
only inflammation but also matrix remodeling in
chronic inflammatory disease like COPD. An antisense
antagonist for NF-κB p65 is now in clinical trial phase I
for Crohn’s disease . 
Another class of kinases regulate activation of signal-
ing proteins. The biaryl-urea-derivate BAY 43-9006 is a
dual inhibitor of Raf kinase and VEGFR being tested in
clinical phase III studies for treatment of cancer
(113,114). This drug impairs tumor growth and angio-
genesis. Recently, Hewson et al. (115) showed that
MUC5AC expression by airway epithelial cells needed
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Ras and Raf activation downstream from EGFR activa-
tion. Hence, BAY 43-9006 may potentially reduce
growth factor receptor tyrosine kinase-induced prolifer-
ation or MUC5AC expression as well as vascular
remodeling as seen in COPD.
TGF-βR signal transduction involves the down-
stream-acting Smad transcription factors. This pathway
includes Smad2 and Smad3, which activate TGF-β-
responsive genes, and the inhibitory Smad6 and Smad7
proteins (116). Patients with COPD were observed to
have an unchanged Smad3 expression in the airways,
whereas expression of Smad6 and 7 was lower as com-
pared to patients without COPD (117). In addition, cig-
arette smoke extract reduced the Smad6 and Smad7
expression in alveolar epithelial A549 cells in vitro (117).
SB431542 and the more potent SB505124 inhibit Smad2
and 3 phosphorylation, their nuclear translocation, and
TGF-β-induced collagen I synthesis and tumor cell
death (117,118). These data point to the potential use of
Smad2/3 antagonists or Smad6/7 agonists in the treat-
ment of airway remodeling in COPD.
In conclusion, several inhibitors of MAPK p38 and
NF-κB are at a more advanced stage with respect to
clinical trials, whereas antagonists for Raf, IKK, and
Smad2/3 may also prove to be useful for therapy
against remodeling and inflammation. The potential
disadvantage of using inhibitors of cell signaling mol-
ecules is that these molecules are general signal trans-
duction proteins involved in various physiological
processes. Systemic administration of antagonists
may have profound effects on other receptor-medi-
ated pathways other than the pro-inflammatory and
remodeling reactions in COPD. Moreover, inhibition
of these molecules may also potentially impair
defense and repair mechanisms resulting in increased
infection risk. 
PERSPECTIVES AND CONCLUDING REMARKS
Although imbalance mechanisms between proteases
and antiproteases and oxidants and antioxidants are
thought to prevail in COPD, pathogenetic mechanisms
with regard to tissue remodeling are not yet clarified.
Changes in ECM, epithelial metaplasia in chronic bron-
chitis and asthmatics or apoptosis in emphysema, and
vascular changes can occur. Recent investigations also
point to the potential molecules involved in these
processes, including growth factors and cyto- or
chemokines. Specific antagonist drugs capable of reduc-
ing growth factor and cytokine expression or signaling
are available or being tested. Some seem to be effective
in different inflammatory diseases or in reducing tumor
growth. However, these antagonists have not yet been
tested extensively with regard to reducing the remodel-
ing processes in chronic inflammatory lung diseases.
Experimental models and expression studies suggest
that anti-VEGFR strategies may be of use in patients
with emphysema, whereas anti-HER1 directed strate-
gies may be more useful in patients with pulmonary
mucus hypersecretion as seen in chronic bronchitis and
asthma. This suggests the need of stratification of antag-
onist therapy. However, a complete block of cytokine-
driven or growth factor-dependent repair mechanisms
may be disadvantageous, as defense reactions to infec-
tion may be impaired. Antibiotics may overcome bacte-
rial infection but are not useful as a strategy for treating
viral infections. The efficacy and bioavailablity of bio-
logical drugs may be improved by reducing immuno-
genicity and improving routes of administration.
Finally, restoration of lung tissue structure may be pro-
vided by other drugs such as retinoic acids. Such
approaches, however, must await the first results of
growth factor or cytokine antagonist therapy in chronic
lung diseases. 
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